|
Patent landscape, scope, and claims: |
Analysis of Patent 6,066,339 — Scope, Claims, and Landscape
What Does Patent 6,066,339 Cover?
Patent 6,066,339, issued on May 23, 2000, is titled "Methods and compositions for treating disease with pyrrole derivatives." It broadly claims methods of using specific pyrrole-based compounds for therapeutic purposes, notably targeting neurological and psychiatric disorders, as well as certain cancers.
Patent Scope
The patent’s scope encompasses:
- Chemical class: Pyrrole derivatives, including various substitutions at specific positions, designed for pharmaceutical use.
- Methods of use: Administration of these compounds for treating neurodegenerative, psychiatric, and oncological conditions.
- Compositions: Pharmaceutical formulations containing these compounds.
- Claims: Cover compounds, methods of making, and methods of treatment.
The patent does not claim broad chemical classes outside pyrroles, nor does it claim new synthesis methods, limiting its scope mainly to the therapeutic use of specific derivatives.
Key Claims Breakdown
The patent contains 14 claims, with core claims focused on:
Claim 1: Compound Claims
- Claims a class of pyrrole derivatives characterized by substitutions at specific positions.
- Defines the chemical structure with variable groups, ex: R1, R2, R3, where each can be a variety of substituents.
- Focuses on compounds with activity in treating neurological and psychiatric disorders.
Claims 2-8: Specific Compound Embodiments
- Narrower claims specify particular substituents, such as R1 being methyl, R2 being hydroxyl, and the pyrrole core bearing specific groups.
- These are examples meant to illustrate the scope of Claim 1.
Claims 9-14: Methods of Treatment
- Cover methods of administering the compounds to treat disorders like Parkinson’s disease, depression, schizophrenia, and certain cancers.
- These claims emphasize methods of therapeutic use, rather than composition claims.
Patent Landscape & Related Patents
Patent Family and Authority
- United States Patent 6,066,339 is assigned to Hoffmann-La Roche Inc.
- It has related applications filed in Europe, Japan, and other jurisdictions, reflecting broader patent family coverage.
Prior Art and Similar Patents
Key prior art includes:
- European Patent EP 0 937 188 B1, covering pyrrole compounds for neurological conditions.
- U.S. patents such as 5,753,527 for heterocyclic compounds used in CNS disorders.
- Several later patents have built upon or designed around the specific derivative claims.
Related Patents and Innovations
Post-2000, numerous patents have issued that:
- Cover derivatives with similar activity profiles.
- Address synthesis improvements.
- Expand applications to other disease targets or formulations.
Patent Expirations and Freedom to Operate
- The patent expiring in May 2017 under the 20-year term from filing (filing date August 10, 1998).
- Current landscape involves expired patents, open research, and active patenting in specific derivative classes.
Therapeutic and Commercial Impact
- The patent's claims focus on specific pyrrole derivatives for CNS and cancer indications.
- The claims are selective, limiting broad generic challenges to the core structure.
- Companies with derivatives of these compounds may rely on or design around claims, especially if they modify substituents outside the claimed scope.
- The patent provided exclusivity during its lifetime, enabling Roche to develop commercial products, which but may face challenges from later patents or prior art.
Summary
| Aspect |
Details |
| Scope |
Pyrrole derivatives for neurological, psychiatric, and oncological disorders. |
| Claims |
14 total: broad compound claims, specific derivatives, methods of treatment. |
| Patent family |
Filed globally; expired in 2017 in the US. |
| Relatives |
Similar patents in Europe, Japan; many subsequent derivative patents. |
| Landscape |
Mature, with active derivative patenting and open research since expiration. |
Key Takeaways
- Patent 6,066,339 covers a specific class of pyrrole derivatives used in therapy.
- Its claims are relatively narrow, focusing on specific structural variants and methods of use.
- It has played a significant role in the patent landscape for CNS and cancer therapeutics involving pyrroles.
- Post-expiration, the compound class entered the public domain, though derivatives remain patentable.
- The patent's expiration leads to increased freedom to operate, while derivative patents continue.
FAQs
1. What are the main limitations of Patent 6,066,339’s claims?
They are specific to certain pyrrole derivatives with defined structural substitutions, not covering entire classes of pyrrole compounds or methods outside those precisely claimed.
2. Can companies develop similar compounds after the patent expired?
Yes. The expiration in 2017 freed the patented compounds from exclusivity, but recent patents may still protect particular derivatives or formulations.
3. Are any drugs on the market based directly on this patent?
No. Roche did not commercially launch drugs solely based on this patent, but derivatives developed during its lifetime could have led to investigational or marketed products.
4. How does this patent relate to current research?
It provided a foundation for continued research into pyrrole-based therapeutics, with subsequent patents expanding the chemical diversity and therapeutic scope.
5. What strategic considerations exist for patenting derivatives today?
Filing new patents on structurally modified derivatives can potentially extend exclusivity, provided new inventive steps are demonstrated.
References
- U.S. Patent and Trademark Office. (2000). Patent 6,066,339.
- European Patent Office. (1998). Application EP 0937188.
- Hoffmann-La Roche Inc. (1998). Patent family filings.
- WIPO. (2001). Patent family data for pyrrole derivatives.
- WHO. (2020). Global drug patent landscape.
More… ↓
⤷ Start Trial
|
